A meta-analysis compared the renal side effects of SGLT2 inhibitors in patients with type 2 diabetes.
A meta-analysis published in Diabetes, Obesity, and Metabolism compared the renal side effects of SGLT2 inhibitors.
Randomized trials in patients with T2DM receiving SGLT2 inhibitors and experiencing at least one adverse renal outcome were included.
The results indicated dapagliflozin was associated with a greater risk of composite adverse renal events compared with placebo, and only empagliflozin was associated with a lower risk than placebo. More research is needed by the authors concluded that empagliflozin may have a renal-protective effect.